

General information about company	
Scrip code	524606
Name of company	BERYL Drugs Ltd
Result Type	Main Format
Class of security	Equity
Date of start of financial year	01-04-2017
Date of end of financial year	31-03-2018
Date of board meeting when results were approved	07-07-2017
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	27-06-2017
Description of presentation currency	INR
Level of rounding used in financial results	Thousands
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Pharmaceutical Industry
Start time of board meeting	12:00
End time of board meeting	13:30

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2017	01-04-2017
B	Date of end of reporting period	30-06-2017	30-06-2017
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	48470	48470
	Other income	378	378
	Total Revenue	48848	48848
2	Expenses		
(a)	Cost of materials consumed	26012	26012
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	10905	10905
(d)	Employee benefit expense	1655	1655
(e)	Finance costs	373	373
(f)	Depreciation and amortisation expense	1000	1000
(g)	Other Expenses		
1	Other Expenses	7616	7616
	Total other expenses	7616	7616
	Total expenses	47561	47561

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2017	01-04-2017
B	Date of end of reporting period	30-06-2017	30-06-2017
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Profit before exceptional and extraordinary items and tax	1287	1287
4	Exceptional items	0	0
5	Profit before extraordinary items and tax	1287	1287
6	Extraordinary items	0	0
7	Profit before tax	1287	1287
	Current tax	320	320
	Deferred tax	0	0
	Total tax expenses	320	320
9	Net Profit Loss for the period from continuing operations	967	967
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax	0	0
13	Profit (loss) for period before minority interest	967	967
16	Net profit (Loss) for the period	967	967

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-04-2017	01-04-2017
B	Date of end of reporting period	30-06-2017	30-06-2017
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
17	Details of equity share capital		
	Paid-up equity share capital	50717	50717
	Face value of equity share capital	10	10
17	Details of debt securities		
18	Reserves excluding revaluation reserve		
20	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	0.191	0.191
	Diluted earnings (loss) per share from continuing and discontinued operations	0.191	0.191
24	Disclosure of notes on financial results	Textual Information(1)	

Text Block	
Textual Information(1)	<ol style="list-style-type: none">1. The Standalone results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting held on 07th July 2017.2. In accordance with the requirements of Clause 41 of the Listing Agreement with the Stock Exchange, the Statutory Auditors have performed a limited review of the Company's financial results for the quarter ended June 30, 2017 there are no qualifications.3. The Income from Operations is from one segment namely "Pharmaceutical Industry".4. Previous period exp. have been regrouped / rearranged, wherever necessary.5. taxes and depreciation are calculated on proportionate basis on annual estimated basis.6. There were no Investors complaints pending at the beginning of the quarter and one complaint were received during the quarter ended June 30, 2017.

